Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,855 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Degenerative Disorder Clear all
Completed Phase 2 Interventional Results available

Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)

NCT00935883
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Eculizumab, Saline
Drug
Lead sponsor
Philip J. Rosenfeld, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device

NCT01103505
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
ForeseeHome AMD Monitoring Device
Diagnostic Test
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
55 Years and older
Enrollment
1,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
38
States / cities
Little Rock, Arkansas • La Jolla, California • Loma Linda, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

NCT03631407
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Vicriviroc, Pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Scottsdale, Arizona • Encinitas, California • Fresno, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 16, 2026, 4:40 PM EDT
Withdrawn Phase 3 Interventional

Peri-Incisional Drug Injection in Lumbar Spine Surgery

NCT03513445
View directory record Official record
Conditions
Lumbar Disc Herniation, Degenerative Disc Disease, Spondylolisthesis
Interventions
Morphine, Epinephrine, naropin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840

NCT04422431
View directory record Official record
Conditions
Wilson Disease
Interventions
Bis-Choline Tetrathiomolybdate
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Sacramento, California • Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 16, 2026, 4:40 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

DC Longitudinal Study on Aging and Specimen Bank

NCT03702907
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment, Aging, Aging Disorder
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
45 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Oct 16, 2026, 4:40 PM EDT
Withdrawn Not applicable Interventional

Comparison of Three Approaches of Electrode Placement to Detect Changes in Motor Evoked Potentials During Spine Surgery

NCT05098431
View directory record Official record
Conditions
Intervertebral Disc Degeneration, Intervertebral Disc Displacement, Spinal Stenosis, Spinal Curvatures, Spondylitis, Spondylosis
Interventions
Quadriceps and Rectus Femoris MEP Recording
Other
Lead sponsor
Allina Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 16, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

NCT02214628
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Fovista® (anti-PDGF BB) plus anti-VEGF
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 16, 2026, 4:40 PM EDT
Not listed Not applicable Interventional

Efficacy of Intradiscal Injection of Viable Placental Tissue Extract in Subjects With One or Two Level, Symptomatic Lumbar Intervertebral Disc Degeneration

NCT02379689
View directory record Official record
Conditions
Degenerative Disc Disease, Pain
Interventions
Injectable placental tissue extract called BioDGenesis (Active Product), Placebo
Drug
Lead sponsor
Semmes-Murphey Foundation
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Puyallup, Washington, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional

Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy

NCT00043680
View directory record Official record
Conditions
Macular Degeneration
Interventions
Celecoxib
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

Intravitreal Aflibercept Injection for Radiation Retinopathy

NCT01579760
View directory record Official record
Conditions
Radiation Retinopathy, Macular Edema
Interventions
Aflibercept every 2 months, Aflibercept monthly
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Not applicable Interventional

Intensive Diet and Exercise for Improving Knee Osteoarthritis in Obese and Overweight Older Adults

NCT00381290
View directory record Official record
Conditions
Osteoarthritis
Interventions
Diet, Exercise
Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
55 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Not applicable Interventional

A Long-Term Monitoring Study of the IMT-002 Patients

NCT00976235
View directory record Official record
Conditions
Macular Degeneration
Interventions
IMT - Implantable Miniature Telescope
Device
Lead sponsor
VisionCare, Inc.
Industry
Eligibility
55 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
28
States / cities
Tucson, Arizona • Irvine, California • Los Altos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration

NCT01941082
View directory record Official record
Conditions
Macular Degeneration
Interventions
RO6867461
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Colorado Springs, Colorado • Baltimore, Maryland • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

NCT02698566
View directory record Official record
Conditions
Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Paducah, Kentucky • Charlotte, North Carolina • Chattanooga, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 16, 2026, 4:40 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)

NCT04124029
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury, Mild Cognitive Impairment
Interventions
No Intervention is used for this study but all subjects will be asked to complete electroencephalogram (EEG) testing and an MRI scan., No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
Device · Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
30 Years to 90 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Terminated Phase 3 Interventional

A Clinical Study of the Dynesys(R) Spinal System

NCT00759057
View directory record Official record
Conditions
Degenerative Spondylolisthesis or Retrolisthesis, Spinal Stenosis, Stenosing Lesion.
Interventions
Posterior Pedicle Screw System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
20 Years to 80 Years
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
26
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 16, 2026, 4:40 PM EDT
Recruiting Not applicable Interventional

The Ailliance Post-Market Clinical Study

NCT05856370
View directory record Official record
Conditions
Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma, Spinal Tumor Case
Interventions
Follow-up schedule: pre-operative baseline up to 24-months post-procedure
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
23
States / cities
Tucson, Arizona • Little Rock, Arkansas • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

NCT03834753
View directory record Official record
Conditions
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
bevacizumab, ranibizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
50
States / cities
Tucson, Arizona • Arcadia, California • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Active, not recruiting Phase 2 Interventional

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

NCT05230537
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Iptacopan (LNP023), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
22
States / cities
Fullerton, California • Huntington Beach, California • Rancho Cordova, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

NCT03642067
View directory record Official record
Conditions
Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
Interventions
Nivolumab, Relatlimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 16, 2026, 4:40 PM EDT
Recruiting Phase 2 Interventional

Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD

NCT04735263
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Atorvastatin 80mg
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
50 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Study Comparing Regional Anesthetic Blocks and Periarticular Infiltration for the Management of Post-operative Pain After Direct Anterior Total Hip Arthroplasty

NCT02904993
View directory record Official record
Conditions
Degenerative Joint Disease
Interventions
L2 paravertebral block, periarticular injection group
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease

NCT03539952
View directory record Official record
Conditions
Wilson Disease
Interventions
Penicillamine (D1-W12), TETA 4HCL (W12-60), Penicillamine (W12-W60), TETA 4HCL (60-<W108)
Drug
Lead sponsor
Orphalan
Industry
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 16, 2026, 4:40 PM EDT